Ty Young

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Juva Life Sells Subsidiary Facility and Offers a Look at Stockton Cultivation and Delivery Activity

–Mark this date: May 25^th for upcoming live online information session

VANCOUVER, BC, — (GLOBE NEWSWIRE – April 4, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products is pleased to announce the sale of an underutilised physical asset for the net sum of $1.1 million (USD), and offers a look at the commercial cannabis cultivation and delivery activity underway at its Stockton, California facility.

As noted in a news release on November 25, 2020, Juva identified its two assets located in Stockton, California as the San Juan and Navy Drive facilities. The 30,000 sq. ft. San Juan facility is progressing at a rapid pace and the Company subsequently determined the nearby 11,500 sq. ft. Navy Drive facility was nonessential and elected to find a buyer. Juva’s indirect wholly owned subsidiary, VG Enterprises, LLC which had held title on the facility since 2018 and had applied for and received several key permits regarding certain proposed cannabis-based cultivation operations, was able to successfully effect a purchase agreement with a local buyer which included the facility and permits. The agreement sets forth the terms and conditions of the sale at the agreed upon net purchase price of $1.1 million (USD), the proceeds of which will be utilized by Juva for business development purposes. Details of the agreement are available at www.sedar.com.

In related news, the highly active Stockton location is rapidly moving forward with the interior build-out of the facilities and ongoing cultivation activities. As noted previously, to accelerate the first two harvests, VP of Horticulture, Thomas Leschak and his team elected to expedite timelines by utilizing fully propagated cannabis clones provided by a 3^rd party. The results have been outstanding and the Juva team is confident its first crop will be harvested on or by May 13, 2021. The horticulture team are already looking ahead and have selected cultivars from our extensive genetics inventory for introduction into our ongoing commercial production.

Company Founder and CEO, Doug Chloupek advises, “Our activities in Stockton are really coming together nicely. We realized the two facilities were too close together and Navy Drive was simply too small, so the sale made perfect sense. The price was right, and we were pleased to find an interested buyer quite quickly. Our remaining Stockton facility is now our prime asset in this outstanding territory.”

“We have made incredible progress at the San Juan facility and I wanted to let everyone have a behind the scenes peek at what we have been up to. Consequently, we arranged a photo shoot to share our progress with our shareholders,” notes Chloupek. “I invite everyone to take a look at the photos on the cultivation page of our website and bookmark the page for reference as we plan to add more images in future.” Click Here to View Photos.

“Lastly, and speaking of bookmarks, please mark this date: Tuesday May 25^th, for an opportunity to watch a live presentation and Q&A session I will be offering on that day.” Doug continues, “More information will be provided in our next news release and on our website regarding times and ways to access the presentation. I sincerely look forward to your participation as we hope to provide meaningful insights regarding our plans for value generation, commercial activities, research efforts and ongoing strategic plans.”

For those new to the Juva story, please visit our website at www.juvalife.com and make sure you visit https://juvalife.com/stockton/ to view the photo gallery.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Juva Life Enrolls First Human Subject in Cannabis Registry Study

– Achieves 1^st Step in Design and Validation of Clinical Platform
to Standardize Clinical Effect and Mode of Action

VANCOUVER, BC, — (GLOBE NEWSWIRE – March 9, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California-based life science company today announced the enrollment of the first human subject into its “Natural History of Disease: Cannabis Registry” Clinical Study. The establishment of this controlled patient registry study is Juva’s first step in establishing the clinical methodology to efficiently gauge the clinical effect of various cannabis-based formulations on human subjects.

Juva Life is focused on developing safe, evidence-based cannabis products. Juva has developed a technology platform that consists of chemistry, clinical and data science that enables the Company to learn how cannabis works at a fraction of the cost compared to competitors. Juva’s initial focus is generally centered on inflammation-defining compositions of matter suitable for consumer and pharmaceutical product development.

The intent of what is known as “the IMPACT Registry” is to develop real-world clinical evidence for cannabis-based products under development. Initial clinical indications being targeted include, but are not limited to pain, sleep, appetite, and other indices of normal function. For more information: https://clinicaltrials.gov/ (ID NCT04726254). The study allows for significant data collection and was assigned a prospective timeline with a start date of February 15, 2021 approved to February 15, 2025. Step one accrual of the multi-faceted registry is aimed to be completed by Q4 of 2021.

In parallel to initiating the clinical registry study, the company is undertaking a systematic evaluation of cannabis formulations in gold-standard pre-clinical laboratory models with respect to anti-inflammatory mode of action. Data obtained in both the clinical and pre-clinical studies will be analyzed together, with the intention of benchmarking formulations to accelerate dose finding and clinical endpoint finding.

Data to be recorded includes:

Basic demographics of patients using cannabis-based medicaments.
Disease diagnoses and symptoms for which patients are seeking management.
Cannabinoid formulation, chemical composition, amount (in milligrams), dose and utilization.
Patient Reported Outcomes (PRO) for sleep, pain, appetite, and other indications
Concomitant use of other anti-inflammatory or analgesic medications
Overall impact on clinical or patient treatment plans.

Vice President of Chemistry for Juva Life, Sanjeev Gangwar Ph.D. states, “Today’s milestone announcement notes our first patient enrollment, but we will quickly surpass this with many others joining the study. The work we are undertaking is critical so that consumers, patients, doctors, regulators, and our prospective partners can gain from well controlled scientific studies that employ FDA equivalent standards. The need for new, safe, and evidence-based cannabis products which target un-met medical needs is large. This is clearly evidenced by the recent $7.2 billion acquisition of the makers of Epidiolex, currently the only FDA-approved drug containing CBD which solely addresses seizures in rare diseases like severe forms of epilepsy. We are aiming to address numerous conditions and in so doing hope to build commensurate value. We look forward to announcing additional advances regarding our registry as well as initial plans for our chemistry program in the coming weeks as we continue to accelerate our efforts.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.

JUVA LIFE INC. COMPLETES $10 MILLION PRIVATE PLACEMENT

VANCOUVER, BC – February 19, 2021 – Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“Juva” or the “Company”) a California based life sciences company focused on the research, development and commercialization of cannabis products is pleased to announce that it has completed its previously announced private placement of special warrants of the Company (the “Special Warrants”), at a price per Special Warrant of $1.05, and issued an aggregate 9,528,578 Special Warrants (including over-allotment option) for total gross proceeds of $10,005,006.90 (the “Offering”). The Offering was conducted by Mackie Research Capital Corporation as sole bookrunner and lead agent on a commercially reasonable “best efforts” private placement basis.

Each Special Warrant shall be automatically exercisable into one unit of the Company (each a “Unit”), as described below. Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share (each, a “Warrant Share”) at a price of $1.35 per Warrant Share until February 18, 2023.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is the date on which the Company obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”), and (ii) the date that is four months and one day after the closing of the Offering.

In connection with the Offering, the Company paid cash fee in the amount of $732,769.23, plus expenses and applicable taxes, and issued a total of 666,999 broker warrants and advisory warrants (together, the “Compensation Warrants”). Each Compensation Warrant is exercisable to purchase one Unit, at $1.05 per Unit, until February 18, 2023.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The Company will use its commercially reasonable efforts to obtain a receipt from the Securities Commissions for the Qualifying Prospectus within 120 days of the closing of the Offering (not including the date of closing), provided, however, that there is no assurance that a Qualifying Prospectus will be filed or that a receipt therefor will be issued by the Securities Commissions prior to the expiry of the statutory four month hold period.

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus before the date that is 120 days following the closing of the Offering (not including the date of closing), each unexercised Special Warrant will thereafter entitle the holder to receive, upon the exercise thereof, for no additional consideration, one-and-one-tenth (1.10) Unit (instead of one Unit).

Prior to the filing of the Qualifying Prospectus and the automatic exercise of the Special Warrants, the securities issued under the Offering will be subject to a four month hold period from the date of closing of the Offering in addition to any other restrictions under applicable law.

The securities offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. These forward looking statements include, but are not limited to, the closing of the Offering, the intended use of the proceeds of the Offering and the filing of a prospectus to qualify the Units. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forwardlooking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com.

Juva Life Inc. Announces $5 Million Private Placement

VANCOUVER, BC – February 02, 2021 – Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“Juva” or the “Company”) a California based life sciences company focused on the research, development and commercialization of Cannabis products is pleased to announce that it has entered into a letter of engagement with Mackie Research Capital Corporation (“Mackie”), pursuant to which Mackie, acting as sole bookrunner and lead agent, has agreed to offer for sale, together with a syndicate of agents (together with Mackie, the “Agents”), Special Warrants of the Company (the “Special Warrants”), on a commericallyy reasonable “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $1.05 (the “Issue Price”) for total gross proceeds of up to $5,019,000 (the “Offering”). The minimum subscriprion amount is $25,000.

Each Special Warrant shall be automatically exercisable into units of the Company (the “Units”), as described below. Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $1.35 per Share for a period of 24 months following the Closing Date.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is three business days following the date on which the Company obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”), and (ii) the date that is four months and one day after the Closing of the Offering (the “Qualfication Date”).

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus before the date that is 30 days following the closing of the Offering (not including the date of closing), each unexercised Special Warrant will thereafter entitle the holder to receive, upon the exercise thereof, for no additional consideration, one-and-one-tenth (1.10) Unit (instead of one Unit) and thereafter at the end of each additional thirty (30) day period prior to the Qualification Date, each Special Warrant will be exercisable for an additional 0.02 of a Unit.

The Company has granted the Agents an option to offer for sale up to an additional 15% of the Special Warrants, at the Issue Price, exercisable in whole or in part at any time for a period of up to 48 hours prior to the closing date of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The securities being offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forwardlooking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**

Juva Life Advances Intellectual Property Protection Program and Advises on DTC Eligibility

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 27, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research and development, and commercialization of Cannabis products is pleased to offer an update regarding intellectual property protection matters and concurrent capital markets activities.

Juva Life is a life science company focused on the identification and characterization of evidenced based safe cannabis products. The Company has developed a unique platform that enables the identification of products targeting inflammatory conditions. Juva will protect these inventions through holding as trade secret certain discovery technologies and patenting novel compositions of matter and uses. Directing these activities within the Company is Sanjeev Gangwar, Ph.D., Vice President of Chemistry. Dr. Gangwar brings significant experience to this subject matter having served as a Director of Oncology Discovery Chemistry for Bristol-Myers Squibb, and a co-inventor of 45 patents.

In addition, the Company will expand its commercial trademarks. To-date, Juva has filed applications for 24 trademarks across multiple classes and goods including brand identity, brand messaging and products. The filings span multiple jurisdictions including the USA, Canada, the European Union (EUTM), and globally through the United Nations’ World Intellectual Property Organization (WIPO).

Company Founder and CEO, Doug Chloupek states, “We view the codification of our IP strategy critical to our sustainable competitive advantage which drives our commercialization and partnering plan. Our goal is to generate revenue through commercialization and to deploy revenue to discover and protect valuable and licensable products.”

In related news, the Company is pleased to announce that electronic settlements of its OTCQB-traded shares in the United States have received approval from The Depository Trust Company (“DTC”) of New York, NY and are now DTC eligible.

The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

“We are incredibly pleased to have secured DTC eligibility to facilitate the trading of our common shares for U.S investors and brokerage firms,” Chloupek stated. “This greatly simplifies the process of trading the Company’s common stock on the OTC marketplace in the United States allowing for faster execution and improved liquidity which will help broaden our investor base.”

In addition to the OTCQB, shares of Juva Life also continue to trade on the Canadian Securities Exchange (CSE) and Frankfurt stock exchange.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Juva Life Receives California Cultivation License for Stockton Facility

— Milestone Event to Spur Revenues and Product Development Pathway for Unmet Medical Needs

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 19, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is extremely pleased to announce receipt of a state approved cannabis cultivation license for its almost 30,000 sq. ft. facility located in Stockton, California.

After approximately 30 months of dedicated effort encompassing a comprehensive regional and municipal permitting process, extensive physical upgrades, and state of the art equipment installations, Juva has received a greenlight from CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture (CDFA). The agency ensures public safety and environmental protection by licensing and regulating commercial cannabis cultivators statewide. CalCannabis also manages the state’s track-and-trace system, which tracks all commercial cannabis and cannabis products—from cultivation to sale.

With licensing approval, Juva is now moving swiftly to fully activate its newly upgraded facility by planting approximately 8,000 sq. ft. of flowering canopy and 5,000 sq. ft. of non-flowering canopy. An additional 4,500 sq. ft. of space has been subdivided into trim, dry storage, breeding, pre-roll, packaging, and environmental system rooms (including automated controls, water reserves, fertilization, and irrigation, etc.). Three of the five growing spaces are ready for immediate planting with another two expected to be completed by Q2, 2021. Once all five rooms are fully operational, the facility is expected to have the annual capability to produce approximately 6,000-pounds of high-quality cannabis flower. Cultivated flower production is slated for use in Juva branded products, contract production services, and clinical research targeting novel product formulations.

In addition, the facility includes almost 3,000 square feet of space for use as a delivery, packaging and distribution center. As of October 2020, Juva has operated a growing cannabis delivery fleet from this location, offering nearly 400 product SKU’s to the approximately 750,000 residents of San Joaquin County. Plans for 2021 include expanded delivery services to the municipalities of Tracy (to the west), Modesto, (to the south) and Elk Grove (to the north).

The facility provides the residential delivery service separately from the distribution center which is designed to service B2B shipping of bulk cannabis to other licensed cannabis businesses (including related Juva facilities) as well as planned distribution of Juva branded products. The entire facility has been outfitted to be completely powered by low emission onsite natural gas generators so that electrical grid power serves as a system backup in order to reduce electrical operating costs by as much as 50%.

Company Founder and CEO, Doug Chloupek states, “This is a milestone event for Juva. Now that we can commence cultivation, we are firmly in charge of our destiny. We can control product quality and output in order to service our growing enterprise, as well as generate quantifiable returns. Our strategy integrates a path to sustainability and an ability to advance the development of novel formulations to address a myriad of unmet medical needs around the world. Todays announcement is a huge step forward and validation of our business plan to build value at every step of the process.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Juva Life Unifies and Accelerates Brand Marketing Plans

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 14, 2021) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations, is pleased to announce an upcoming strategic brand identity campaign designed to unify its messaging amongst its various products and divisions.

Juva Life is working to unify its communication strategy and advance its brand positioning in order to more consistently represent its core mission across multiple platforms and media. The Company is embarking on an accelerated plan for growth, and as such, the need for responsible broad public awareness is increasingly paramount for the long-term success of the Company.

Company Founder and CEO, Doug Chloupek states, “Our Life Sciences efforts are instrumental for the strategic success of Juva. While our efforts to-date have laid the foundation for a solid regional cannabis enterprise, we are actively pursuing opportunities aimed at delivering a platform of products that address significant unmet medical needs. The marketing efforts required to drive awareness of our activities includes considerable forethought and planning to ensure consistent messaging to appropriately communicate the various aspects of our product development strategy. We are dedicated to laying a solid foundation for commercial success by executing a comprehensive strategic marketing plan.”

The Company has implemented a scalable approach to marketing by engaging contract vendors who meet the requisite needs for creative expertise, cost-effective methodologies, and the ability to provide a long-term perspective in a fast-paced, evolutionary environment.

As a result, Juva is incredibly pleased to be working with a growing team that includes The Idea Cooperative, a dedicated full-service creative agency of Sonoma County, California who have taken the lead role in consumer-facing brand positioning and product design. Their talents are focused on website, social media, newsletters, and other related commercial communications strategies. In addition, Juva has engaged the highly experienced, full-service design team at August Studio of Oakland, California to integrate a consistently branded look and feel throughout its brick-and-mortar facilities.

In related news, the Company has engaged investment communications, financial research, and integrated digital marketing service providers to increase public awareness regarding Juva’s activities, strategic plans, and investment opportunity. As part of Juva’s disclosure obligations as a public issuer, the terms and fees for investor relations service providers are six (6) month engagements and include Advanced Media Solutions Ltd. at $450k, Promethean Marketing Inc. at $350k, and Digitonic at $150k.

Together, these creative, communications and marketing agencies are shaping the future brand identity and public awareness of Juva Life.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Juva Life Transforming Ex-Cancer Research Facility into Flagship Operation

– Hayward Research Laboratory Positioned to Drive ‘Science of Cannabis’ Efforts

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 22, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to provide an update regarding activities at its Hayward, California facility build-out.

Originally constructed and partially funded by federal research grants, Juva Life’s Hayward project started life as biotechnology cancer research facility focused on the development of plant-based antibodies and the study of protein expression in tobacco plants. As such, the structures on the property includes 18,000 sq. ft. of preexisting purpose-built concrete structures adjoining 11,000 sq. ft. of dedicated greenhouse canopy.

As part of the legacy infrastructure and a key feature in Juva’s future ambitions, the main building includes an ISO Class 5 cleanroom ideally suited to propel Juva’s science of cannabis strategy towards the development of advanced formulations and products. The cleanroom and adjoining laboratory spaces include plans for the installation of liquid and gas chromatography plus mass spectrometry equipment. Class 5 is considered at the more critical end of the class spectrum, requiring a greater level of filtration to achieve a level of cleanliness by typically employing Ultra Low Penetration Air (ULPA) Filtration targeting 99.9995% efficiency at 0.12 micron. This research facility is scheduled to be one of the first operational elements of the Hayward campus.

A Conditional Use Permit (CUP) was approved on October 22^nd upon completion of an extremely rigorous and thorough application process. The application included many details typically included in building permit applications and, as such, it is believed may expedite additional permitting. Upon approval, immediate actions require the installation of physical perimeter security and modernized fire suppression systems. Upon installation, the Company will apply for partial occupancy to enable the outfitting of the laboratory and related processing areas in order to initiate extraction and formulation operations which are anticipated to scale to full production by mid-2021.

Upon completion of the proposed renovations, greenhouse cultivation is conditionally approved for 13,453 sq. ft. within a fully modernized facility. An internal assessment suggests that material yields of up to 4,600 pounds of total biomass inclusive of 3,600 pounds of flower could be harvested in the first full year of activity. Advanced agronomic practices within the controlled environment are anticipated to produce quantifiably premium quality and potency. The Hayward facility will ultimately total 38,000 sq. ft. in size with a manufacturing focus on advanced industrial scale extraction processes utilizing most of the internally harvested material for use in novel formulations, product development, and material supply for Juva’s related divisional activities.

Related activities planned for the Hayward campus include business to consumer (B2C) retail delivery operations offering Juva-produced and 3^rd party products throughout the Eastern San Francisco Bay area. Acting as a distribution center, Juva would have the ability to ship bulk or processed product to other licensed cannabis businesses (including other current or future Juva facilities). In addition, the Company has been conditionally approved to develop a boutique flagship retail operation focused on Juva products in a designer-styled environment.

Juva’s CEO and Founder, Doug Chloupek states, “We were extremely fortunate to discover the Hayward location early in our planning phase. The previous occupants’ operations provide us with a pre-built facility that closely matches our strategic aims and consequently expedites our ability to advance operations. I’m particularly excited that it appears our lab could be functional early to mid 2021, as the development of a broad spectrum of product formulations through applied science is a fundamental aspect of how we aim to build corporate and shareholder value.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Juva Life Features Redwood City Operational Update

— Cannabis delivery services position Juva for post pandemic brand loyalty and growth

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 15, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to follow up on its November 25th news release with a featured summary of activities to-date at its Redwood City operations.

In relation to the significantly larger footprint of the Hayward and Stockton facilities which are rapidly advancing through licensing and construction phases, the Redwood City operation was designed to initially target regional delivery services and rapid territorial expansion. With a growing staff of over 14 team members and an expanding vehicle fleet which currently includes 50% hybrid electric vehicles, the service has been operational since late January of 2020.

With a functional capability to easily service the San Francisco Peninsula through its central location halfway between San Francisco and San Jose, the location serves a generally younger demographic in the Silicon Valley region. Ongoing efforts are underway to extend the delivery area to encompass adjacent high density urban centres aimed at increasing the total accessible population to an estimated 1.67 million potential customers.

Through an evolving menu of almost 400 SKU’s to choose from, including numerous award-winning and top selling products, the Juva sales team is constantly improving conversion rates and building a loyal customer base. For more information on product services, visit: www.shopjuva.com/redwood-city/.

In related news, the Company has recently obtained the option to lease a high visibility retail location on a prime corner of downtown Redwood City in a concerted bid to receive one of up to six storefront retail licenses proposed to be granted via a merit-based process by the municipality of Redwood City. Working in conjunction with the existing delivery services operational center for inventory support, the addition of storefront retail could act as a regional brand multiplier and centralized focus for enhanced consumer awareness campaigns.

Juva’s CEO and Founder, Doug Chloupek notes, “COVID-19 created some surprising opportunities and interesting challenges that our team have been able to pivot to our advantage. As a brand-new delivery service offering an extensive menu of popular items, we really had to quickly build confidence based on quality, responsiveness, merit and trust. To-date, we have successfully proven to our growing list of customers that with Juva, they can easily order the products they want, when they want, and where they want them. As news regarding vaccine rollout build hope for future, we believe we are extraordinarily well positioned to leverage our commercial activities to quickly advance marketing momentum and increase our sector positioning as, and when restrictions begin to ease. We have worked hard to get the word out during these challenging times and our efforts will definitely act as a launch pad for continued growth and greatly assist in the creation of sustainable value for our entire enterprise.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Forward Looking Statement

The CSE does not accept responsibility for the adequacy or accuracy of this release.